iPSC-derived natural killer cell therapy - Nuwacell Biotechnologies
Alternative Names: iNK cell therapy- Nuwacell BiotechnologiesLatest Information Update: 10 Mar 2024
At a glance
- Originator Nuwacell Biotechnologies
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 10 Mar 2024 Nuwacell Biotechnologies has patent protection for iPSC technology (Nuwacell Biotechnologies pipeline, March 2024)
- 07 Feb 2024 Preclinical trials in Solid tumours in China (Parenteral) (NCT06245018)
- 01 Feb 2024 Nuwacell Biotechnologies plans a dose escalation and extension trial for Solid tumour (NCT06245018)